Atossa Therapeutics Inc
atossatherapeutics.comWhat Do They Do?
Develops an oral medicine candidate for breast cancer and breast conditions, and explores its use in rare diseases.
10-K for FY2025, filed Mar 25, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 7, 2026
−$8.5MView ↗
- ▲ +1% (Loss)
- vs −$8.4M in Q2 FY2025
-
Apr 16, 2026
Settles endoxifen patent disputes and allocates certain fields
The agreement resolves pending patent challenges and preserves Atossa’s development and commercialization of Z-endoxifen in its principal therapeutic areas.
Sources
8-K, filed Apr 16, 2026
On April 16, 2026, Atossa Therapeutics, Inc. (the “Company”) announced that on April 13, 2026, the Company entered into a Settlement…View ↗
Rare-disease programs
The older report describes the company as focused on breast cancer and breast conditions; the latest report also describes exploring a medicine for rare diseases, including muscular dystrophy and McCune-Albright syndrome.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 25, 2026We are a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in…View ↗
Loading...
